Company profile: MYR Pharma
1.1 - Company Overview
Company description
- Provider of biotechnological treatments focused on hepatitis B and hepatitis D.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to MYR Pharma
Visby Medical
HQ: United States
Website
- Description: Provider of instrument-free PCR diagnostic tests for infectious disease detection, including the single-use Sexual Health Test that detects Chlamydia, Gonorrhea, and Trichomoniasis from self-collected vaginal swabs in under 30 minutes, and the Respiratory Health Test that detects and differentiates COVID-19, Influenza A, and Influenza B via nasopharyngeal swabs in under 30 minutes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Visby Medical company profile →
Chembio Diagnostics
HQ: United States
Website
- Description: Provider of proprietary rapid point-of-care diagnostic tests, developing, manufacturing, licensing and marketing DPP assays for HIV 1/2, HIV-Syphilis, Zika (IgM/IgG in Europe; IgM in the USA), Ebola antigen (USA), and Zika-Chikungunya-Dengue (Europe). Portfolio includes two FDA PMA-approved, CLIA-waived rapid HIV tests marketed in the U.S. by Alere (formerly Inverness Medical Innovations).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Chembio Diagnostics company profile →
Lodo Therapeutics
HQ: United States
Website
- Description: Provider of drug discovery and development focused on creating naturally derived novel therapeutics to impact global human health, working in partnership with global pharmaceutical companies and leading NGOs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lodo Therapeutics company profile →
Diagnostic Hybrids
HQ: United States
Website
- Description: Provider of cellular and molecular diagnostic kits and systems for detecting respiratory diseases, herpes infections, thyroid function, and other disease markers. Offers the D3 FastPoint L-DFA influenza A/B identification kit; Vitros Integrated, Chemistry, and Immunoassay Systems with broad, waterless testing menus; Ortho Vision Swift analyzer for automated donor typing; and Lyra real-time PCR assays that simplify sample processing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diagnostic Hybrids company profile →
NanoViricides
HQ: United States
Website
- Description: Provider of nanomedicine-based antiviral therapeutics, developing broad-spectrum candidates including NV-387 (RSV, smallpox, mpox, influenza A), NV-CoV-2 for COVID-19 and potentially long COVID (Phase 1a/1b), NV-CoV-2-R with remdesivir, and NV-HHV-1 for shingles rash, leveraging the TheraCour platform and the HerpeCide program for herpes infections (cold sores, genital ulcers, keratitis).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NanoViricides company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for MYR Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to MYR Pharma
2.2 - Growth funds investing in similar companies to MYR Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for MYR Pharma
4.2 - Public trading comparable groups for MYR Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →